Publications by authors named "Chaja Jacobs"

Claim this Profile
C
Cholesterol homeostasis and lipid raft dynamics at the basis of tumor-induced immune dysfunction in chronic lymphocytic leukemia.
Chaja F Jacobs, Fleur S Peters, Elena Camerini, Gaspard Cretenet, Joanne Rietveld

Cell Mol Immunol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab monotherapy in refractory warm autoimmune hemolytic anemia and cold agglutinin disease.
Marit Jalink, Chaja F Jacobs, Jahanzaib Khwaja, Dorothea Evers, Coty Bruggeman

Blood Adv· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiological, pathological and surgical outcomes after neoadjuvant endocrine treatment in patients with ER-positive/HER2-negative breast cancer with a clinical high risk and a low-risk 70-gene signature.
Josefien P van Olmen, Chaja F Jacobs, Sanne A L Bartels, Claudette E Loo, Joyce Sanders

Breast· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
T-cell dysfunction by pseudohypoxia and autocrine purinergic signaling in chronic lymphocytic leukemia.
Chiara Montironi, Chaja F Jacobs, Gaspard Cretenet, Fleur S Peters, Bauke V Schomakers

Blood Adv· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib plus Obinutuzumab as Frontline Therapy for Chronic Lymphocytic Leukemia Is Associated with a Lower Rate of Infusion-Related Reactions and with Sustained Remissions after Ibrutinib Discontinuation: A Single-Arm, Open-Label, Phase 1b/2 Clinical Trial NCT0231576.
Januario E Castro, Paula A Lengerke-Diaz, Juliana Velez Lujan, Michael Y Choi, Eider F Moreno-Cortes, Chaja Jacobs

Adv Hematol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Kinase inhibitors developed for treatment of hematologic malignancies: implications for immune modulation in COVID-19.
Chaja F Jacobs, Eric Eldering, Arnon P Kater

Blood Adv· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib reduces obinutuzumab infusion-related reactions in patients with chronic lymphocytic leukemia and is associated with changes in plasma cytokine levels.
Juliana Velez Lujan, Paula A Lengerke-Diaz, Chaja Jacobs, Eider F Moreno-Cortes, Cesar A Ramirez-Segura

Haematologica· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis